Rituximab for follicular non-Hodgkin lymphoma.
Gajraj
Elangovan
E
Chung
Helen
H
Longson
Carole
C
Stevens
Andrew
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab